We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
(+32%)
Cap. Flow
+$142M
Cap. Flow
% of AUM
5.42%
Top 10 Holdings %
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33
Avg Time Held Equity + Options
4.2
quarters
Top 10 Avg Time Held Equity + Options
5.4
quarters
Top 20 Avg Time Held Equity + Options
5.4
quarters
Avg Time Held Equity only
4.4
quarters
Top 10 Avg Time Held Equity only
5.4
quarters
Top 20 Avg Time Held Equity only
5.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$64.1M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$36.1M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$31.4M |
| 4 |
Puma Biotechnology
PBYI
|
+$17.7M |
| 5 |
Cymabay Therapeutics
CBAY
|
+$15.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$42.4M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$36.7M |
| 3 |
Radius Health, Inc.
RDUS
|
+$29.2M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$20.9M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.22% |
| 2 | Miscellaneous | 1.22% |
| 3 | Industrials | 0.33% |
| 4 | Consumer Staples | 0.16% |
| 5 | Consumer Discretionary | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Exelixis
EXEL
$14.8B
| $1.12M | 0.04% |
46,361
| – | – |
2016 Q4
3 quarters
|
|
102
Stellantis
STLA
$12.7B
| $1.11M | 0.04% |
62,000
-248
| -0.4% | -$3.43K |
2015 Q2
9 quarters
|
|
103
Lantheus
LNTH
$6.54B
| $957K | 0.04% |
53,763
| – | – |
2016 Q3
4 quarters
|
|
104
GridAI Technologies Corp
GRDX
$33.2M
| $907K | 0.03% |
2
| – | – |
2016 Q4
3 quarters
|
|
105
Centene
CNC
$33.1B
| $748K | 0.03% |
15,452
| – | – |
2017 Q1
2 quarters
|
|
106
Voyager Therapeutics
VYGR
$140M
| $712K | 0.03% |
34,604
| – | – |
2017 Q2
1 quarter
|
|
107
Ferrari
RACE
$68.3B
| $685K | 0.03% |
6,200
| – | – |
2016 Q1
6 quarters
|
|
108
Protara Therapeutics
TARA
$164M
| $668K | 0.03% |
8,353
| – | – |
2014 Q4
11 quarters
|
|
109
Incyte
INCY
$22.6B
| $656K | 0.03% |
5,619
| – | – |
2016 Q3
4 quarters
|
|
110
Vanda Pharmaceuticals
VNDA
$275M
| $649K | 0.02% |
36,232
| – | – |
2017 Q1
2 quarters
|
|
|
HSKA
111
DELISTED
Heska Corp
HSKA
| $643K | 0.02% |
7,300
| – | – |
2017 Q1
2 quarters
|
|
112
Align Technology
ALGN
$9.98B
| $642K | 0.02% |
+3,448
| New | +$590K |
2017 Q3
0 quarters
|
|
|
KERX
113
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $592K | 0.02% |
+83,386
| New | +$600K |
2017 Q3
0 quarters
|
|
114
BeOne Medicines Ltd
ONC
$39.6B
| $590K | 0.02% |
+5,700
| New | +$425K |
2017 Q3
0 quarters
|
|
115
Atara Biotherapeutics
ATRA
$94.2M
| $581K | 0.02% |
+1,404
| New | +$529K |
2017 Q3
0 quarters
|
|
|
PRAH
116
DELISTED
PRA Health Sciences, Inc.
PRAH
| $566K | 0.02% |
+7,427
| New | +$561K |
2017 Q3
0 quarters
|
|
117
DELISTED
Esperion Therapeutics
ESPR
| $540K | 0.02% |
+10,769
| New | +$519K |
2017 Q3
0 quarters
|
|
118
DELISTED
Immunogen Inc
IMGN
| $536K | 0.02% |
+70,126
| New | +$466K |
2017 Q3
0 quarters
|
|
|
PRTK
119
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $532K | 0.02% |
+21,186
| New | +$493K |
2017 Q3
0 quarters
|
|
120
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $511K | 0.02% |
+30,000
| New | +$420K |
2017 Q3
0 quarters
|
|
121
DELISTED
Cutera, Inc.
CUTR
| $495K | 0.02% |
11,981
| – | – |
2017 Q1
2 quarters
|
|
122
Teladoc Health
TDOC
$1.08B
| $485K | 0.02% |
+14,641
| New | +$480K |
2017 Q3
0 quarters
|
|
123
Kyntra Bio
KYNB
$24.8M
| $462K | 0.02% |
+344
| New | +$362K |
2017 Q3
0 quarters
|
|
|
AKAO
124
DELISTED
Achaogen Inc
AKAO
| $439K | 0.02% |
27,551
| – | – |
2017 Q1
2 quarters
|
|
|
NBRV
125
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $431K | 0.02% |
+210
| New | +$493K |
2017 Q3
0 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q3 2017 Portfolio in Review
As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Perceptive Advisors deployed $142M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.
- Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
- Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
- Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
- Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
- Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
- Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
- Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.
Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.